EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical Model

Wendy K Nevala, Liyi Geng, Hui Xie, Noah A Stueven, Svetomir N Markovic

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26073295 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Wendy K Nevala und 4 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, B7-H1 Antigen, Nanoparticles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sorrento Therapeutics (United States), Sorrento Therapeutics, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is a highly aggressive form of breast cancer. Common treatments following surgical resection include PD-1-targeting checkpoint inhibitors (pembrolizumab), as 20% of tumors are PD-L1 positive with or without systemic chemotherapy. Over the last several years, our laboratory has developed nano-immune conjugates (NIC) in which hydrophobic chemotherapy drugs like paclitaxel (PTX) and SN38, the active metabolite of irinotecan, are made water soluble by formulating them into albumin-based nanoparticles (nab) that are hydrophobically linked to various IgG1 monoclonal antibodies, creating an antigen-targetable nano-immune conjugate. To date, we have successfully tested PTX containing NICs linked to either VEGF- or CD20-targeted antibodies in two phase I clinical trials against multiple relapsed ovarian/uterine cancer or non-Hodgkin’s lymphoma, respectively. Herein, we describe a novel NIC created with either PTX or SN38 that is coated with anti-PD-L1-targeting antibodies for the treatment of a preclinical model of TNBC. In vitro testing suggests that the chemotherapy drug and antibody retain their toxicity and ligand binding capability in the context of the NIC. Furthermore, both the PTX and SN-38 NIC demonstrate superior anti-tumor efficacy relative to antibody and chemotherapy drugs alone in a PD-L1 + MDA-MB-231 human TNBC xenograft model, which could translate clinically to patients with TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsB7-H1 AntigenNanoparticlesHumansAnimalsFemaleCell Line, TumorMiceXenograft Model Antitumor AssaysPaclitaxelIrinotecanImmunoconjugates

Stichwörter der Autor:innen

mouse xenograft modelnano-immune conjugate (NIC)programmed death ligand 1 (PD-L1)triple-negative breast cancer (TNBC)

Substanzen

B7-H1 AntigenCD274 protein, humanPaclitaxelIrinotecanImmunoconjugates

Autor:innen und Institutionen

  • Mayo Clinic, 200 1st St SW, Rochester, MN 55905, USA.
  • Vivasor, 9380 Judicial Dr., San Diego, CA 92121, USA.

Förderung

  • Sorrento Therapeutics (United States)
  • Sorrento Therapeutics, Inc.

Zitieren

APA

Nevala, W. K., Geng, L., Xie, H., Stueven, N. A., & Markovic, S. N. (2025). PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical Model. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073295

Vancouver

Nevala WK, Geng L, Xie H, Stueven NA, Markovic SN. PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical Model. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073295

BibTeX
@article{Nevala2025,
  author = {Nevala, Wendy K and Geng, Liyi and Xie, Hui and Stueven, Noah A and Markovic, Svetomir N},
  title = {PD-L1-Targeting Nanoparticles for the Treatment of Triple-Negative Breast Cancer: A Preclinical Model},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26073295}
}
Kostenlos starten →